9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
The DOI matches its Crossref record; 77 of the 81 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although SGLT2 inhibitor use was not incorporated into American Diabetes Association guidelines until 2019,48”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [48]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (40).”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Research works printed but not linked: 6
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lexicon Pharmaceuticals . FDA to review ZynquistaTM (sotagliflozin) as potential treatment for type 1 diabetes [Internet], 2018. Available from http://www.lexpharma.com/media-center/news/673-fda-to-review-zynquista-sotagliflozin-as-potential-treatment-for-type-1-diabetes. Accessed 30 September 2018
- Institute for Clinical and Economic Review . Controversies in the management of patients with type 2 diabetes [Internet], December 2014. Available from https://icer-review.org/wp-content/uploads/2015/03/CEPAC-T2D-Final-Report-December-22.pdf. Accessed 9 November 2018
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
- Lipska, 2017, Human insulin for type 2 diabetes: an effective, less-expensive option, 23
Cited by
Items 501–600 of 773
Esposito, K., Longo, M., Maiorino, M. I., Petrizzo, M., Gicchino, M., Bellastella, G., & Giugliano, D. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107787 · Cited by 7
Kalra, S., Ghosh, S. K., Das, A. K., Nair, T., Bajaj, S., Priya, G., Mehrotra, R. N., Das, S., Shah, P., Deshmukh, V. C., et al. (2020) · Indian Heart Journal · doi:10.1016/j.ihj.2020.01.001 · Cited by 7
Yen, F., Wei, J. C., Liu, J., Hsu, C., & Hwu, C. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13330 · Cited by 6
He, M., Deng, M., Wang, J., Fan, P., Wang, Y., Zhao, X., He, Y., Shi, B., & Sui, J. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9649 · Cited by 6
Mohan, A., Vadhariya, A., Majd, Z., Esse, T. W., Serna, O., & Abughosh, S. (2021) · Patient Education and Counseling · doi:10.1016/j.pec.2020.12.009 · Cited by 6
Prudencio, J. B., Cajudoy, P., & Waddell, D. (2021) · Pharmacy · doi:10.3390/pharmacy9040186 · Cited by 6
Filion, K. B., & Yu, O. H. Y. (2019) · Annals of Internal Medicine · doi:10.7326/m19-1950 · Cited by 6
Wu, H., Fang, X., Jin, D., Miao, R., Wei, J., Zhao, T., Dai, D., Liao, J., Wang, J., Lian, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.827697 · Cited by 5
Ojo, O. A., Ogunlakin, A. D., Ajayi-Odoko, O. A., Gyebi, G. A., Ayokunle, D. I., Olanrewaju, A. A., Agbeye, O. D., Ogunwale, E. T., & Adeyemı, O. S. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-04980-1 · Cited by 5
Metformin recalls: regulatory background, concerns and challenges
Sadasivam, B., Fatima, Z., & Atal, S. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01822-1 · Cited by 5
Valle, C. G.-D., Marco‐Expósito, J. F., Solá, E., Montoya‐Castilla, I., Morillas, C., Hernández‐Mijares, A., & Bañuls, C. (2022) · Nursing Open · doi:10.1002/nop2.1224 · Cited by 5
Gul, N., Rehman, I. U., Shah, Y., Ali, A. M., Ali, Z., Shehzad, O., Goh, K. W., Ming, L. C., & Suleiman, A. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311435 · Cited by 6
“The increasing trend of T2DM is the result of ageing [5], a rapid increase in urbanization [6], obesogenic environments [7], sedentary life-styles [8], an increasing trend in Type 1 DM worldwide as well [9, 10], and genetic susceptibility [11].”
Academic Detailing in the New Era of Diabetes Medication Management
Luo, J., Dancel, E., Bains, S., Fanikos, P., & Fischer, M. A. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1252-0 · Cited by 5
Effective SGLT2 Inhibitor for Patient with Type 2 Diabetes Mellitus (T2DM) and Depression
Shimizu, E., Takehisa, Y., Bando, H., Fujita, M., Kusaka, Y., & Yuu, M. (2020) · doi:10.36502/2020/droa.6160 · Cited by 5
Is metformin use associated with changes in urinary parameters in stone formers?
Rosen, D. C., Bamberger, J. N., Kaplan-Marans, E., Paranjpe, I., Kapoor, A. B., Gallante, B. E., Atashsokhan, D. J., Zampini, A. M., Khusid, J. A., Atallah, W. M., et al. (2021) · Canadian Urological Association Journal · doi:10.5489/cuaj.7344 · Cited by 5
Review Farmakoterapi Diabetes Melitus
Novrianti, I. (2022) · JOPS (Journal Of Pharmacy and Science) · doi:10.36341/jops.v5i2.2411 · Cited by 23
Geist, B. K., Brath, H., Zisser, L., Yu, J., Fueger, B. J., Nics, L., Patronas, E., Kautzky‐Willer, A., Hacker, M., & Rasul, S. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06256-7 · Cited by 5
Peng, W., Yang, B., Qiao, H., Liu, Y., & Yang, L. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2827 · Cited by 5
Ortega‐Pineda, L., Rincon‐Benavides, M. A., Cuellar‐Gaviria, T. Z., Kordowski, M., Guilfoyle, E., Anaparthi, A. L., Lemmerman, L. R., Lawrence, W. R., Buss, J. L., Deng, B., et al. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200173 · Cited by 5
Chiang, C., Kuo, C.-S., Lin, W., Su, J.-H., Chen, J.-D., & Huang, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16122097 · Cited by 5
Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use
Deeks, E. D. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00670-4 · Cited by 5
Wang, X., Liu, J., Huang, L., Zeng, H., He, G., Chen, L., Ma, R., Fu, W., & Ning, B. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029073 · Cited by 5
Ito, Y., Schyndle, J. V., Nishimura, T., Sugitani, T., & Kimura, T. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00710-2 · Cited by 6
Diabetes in the Workplace: the Hazards of Hypoglycemia
Gerbo, R., Jin, C. F., & Clark, K. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1234-2 · Cited by 5
Cicci, J. D., Iyer, P. S., Clarke, M. M., & Mazzella, A. J. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000297 · Cited by 5
Wang, C., Chang, C.-W., Lu, Y., Lam, H., Ku, S.-J., Tseng, K.-B., & Kao, Y.-H. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.11.015 · Cited by 5
Weng, W., Liang, Y. M., Brett, J., Hobbs, T. M., & Baeres, F. M. M. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107500 · Cited by 5
Bando, H., Abe, Y., Sakamoto, K., Hatakeyama, S., Yagi, K., Kobayashi, T., Ogawa, T., Iwatsuki, N., Itagaki, M., Ashikaga, K., et al. (2020) · Diabetes Research - Open Journal · doi:10.17140/droj-6-144 · Cited by 5
Park, J., Han, J., Chang, M., Ki, Y., Kang, J., Yang, H., Cho, H., Park, K. W., Kang, H., Koo, B., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082464 · Cited by 5
Kuang, J., Zhu, J., Liu, S., & Li, Q. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00910-1 · Cited by 5
Freudenberg, D. L., Covington, L. P., Young, R. B., Lopez, N. D., Patel, M. V., & MacLaughlin, E. J. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020958245 · Cited by 5
Ibrahim, L. B., Idowu, P. F., Moses, O. A., Alabi, M. A., & Ajani, E. O. (2021) · Acta chimica slovenica · doi:10.17344/acsi.2020.6212 · Cited by 5
Atal, S., Joshi, R. P., Sadasivam, B., Singh, P., Fatima, Z., & Jain, N. (2020) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_405_20 · Cited by 5
Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function
Welters, A., & Lammert, E. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_474 · Cited by 5
Watada, H., Kawakita, Y., Tanaka, K., Oh, A., Nishigaki, N., Nakajima, T., Fujikawa, K., & Akazawa, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01090-2 · Cited by 5
Corrao, G., Rea, F., Mancia, G., Perseghin, G., Merlino, L. G., Martini, N., Carbone, S., Carle, F., Bucci, A., Carle, F., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.07.014 · Cited by 5
Katz, D. H., & Gavin, M. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-47868-1_2 · Cited by 5
9-N-n-alkyl Berberine Derivatives: Hypoglycemic Activity Evaluation
Khvostov, M. V., Gladkova, E. D., Борисов, С. А., Fedotova, M. S., Zhukova, N., Marenina, M. K., Meshkova, Y. V., Valutsa, N., Luzina, O. A., Tolstikova, T. G., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010044 · Cited by 6
Metformin for Type 2 Diabetes—Reply
Flory, J., & Lipska, K. J. (2019) · JAMA · doi:10.1001/jama.2019.11505 · Cited by 5
Steiger, K. G., SWARNA, K. S., Herrin, J. S., & McCoy, R. G. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09784-0 · Cited by 4
“23 Individual models were adjusted for time period, age, sex, rurality, and cardiovascular and kidney comorbidity as appropriate.”
Ahmed, A. E., Tan, Z., El-Radi, W. A., & Rajamani, K. K. (2025) · Cureus · doi:10.7759/cureus.92175 · Cited by 5
Chen, J., Zhou, D., Zhang, L., Zhang, X., Lv, Z., He, N., & Bao, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-21963-x · Cited by 4
Wang, Y., Liang, Y., Cheung, M. H., Wang, X., Mo, H., Gan, J., Yang, W., Guo, J., & Liang, C. (2025) · Pharmaceuticals · doi:10.3390/ph18111707 · Cited by 4
“Metformin is broadly prescribed for most type II diabetes (T2DM) patients for the improvement of hepatic glucose metabolism and increased peripheral glucose utilization [4].”
Abusamaan, M. S., Fesseha, B., Kim, H. N., Reyes-DeJesus, D., Langan, S. J., Niessen, T. M., & Mathioudakis, N. N. (2020) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2020.100220 · Cited by 4
Rates of Metformin Use in Stage 3b Chronic Kidney Disease Rose After FDA Label Change
Huang, A., Wu, X., Orloff, J. N., Min, J. Y., & Flory, J. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06380-2 · Cited by 4
Hamaguchi, M., Hashimoto, Y., Tanaka, T., Hasegawa, G., Ishii, M., Okada, H., Mitsuhashi, K., Kitagawa, N., Ushigome, E., Yamazaki, M., et al. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211040539 · Cited by 4
Diyabetli Hastalarda Psikolojik İnsülin Direnci Ölçeğinin Türkçeye Uyarlanması
Işık, K., Yıldırım, H., & Cengiz, Z. (2021) · Turkish Journal of Family Medicine & Primary Care · doi:10.21763/tjfmpc.864093 · Cited by 4
Zhang, Q., Zhang, Q., Liu, Y., Yang, S., & Yu, L. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03719-6 · Cited by 4
Tiwari, R. K., Ahmad, A., Chadha, M., Saha, K., Verma, H., Borgohain, K., & Shukla, R. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998294919240506044544 · Cited by 5
NEYER, M., Vogel, J. B., ELSNER, P., Kuehrer, H., Saely, C. H., Muendlein, A., Vonbank, A., MADER, A., Festa, A., Drexel, H., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16084 · Cited by 4
“15 However, the use of GLP-1 agonists remained relatively low in our most recent cohort (OS3) up to 2023.”
for the DPV and DIVE registry initiatives, Hartmann, B., Lanzinger, S., van Mark, G., Wosch, F. J., Durmaz, M., Plaumann, M., Sziegoleit, S., Seufert, J., Holl, R. W., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01409-3 · Cited by 4
Uncommon Presentations of Diabetes: Zebras in the Herd
Shidler, K. L., Letourneau, L. R., & Novak, L. M. (2019) · Clinical Diabetes · doi:10.2337/cd19-0019 · Cited by 4
Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
Shin, J., Kim, H., Kim, C., Kim, C., & Choi, W.-S. (2020) · Korean Journal of Family Medicine · doi:10.4082/kjfm.19.0161 · Cited by 4
Die Behandlung des Diabetes mellitus: Mythen und Evidenz
Göke, B. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03124-9 · Cited by 4
Yeu, R. Q., Brandon, R., Jiang, Y., Griffiths, D., Smallman, K., Moffitt, A., Doherty, G., Paul, R. G., Hindmarsh, J. H., Merriman, T. R., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-036518 · Cited by 4
Trends in Industry Payments to Physicians for Antihyperglycemic Therapies Between 2014 and 2018
Inoue, K., Duru, O. K., Mangione, C. M., & Tsugawa, Y. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06215-0 · Cited by 4
Eby, E. L., Edwards, A. M., Meadows, E. S., Lipkovich, I. A., Benneyworth, B. D., & Snow, K. J. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06603-0 · Cited by 4
Leto, G., Barchetta, I., Candia, L. D., Magotti, M. G., Cianciullo, M., Manti, R., Negri, C., Cimino, V., Dodesini, A. R., Zerella, F., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01137-4 · Cited by 5
Does dietary fat cause a dose dependent glycemic response in youth with type 1 diabetes?
O'Connell, S. M., O'Toole, N. M. A., Cronin, C. N., Saat‐Murphy, C., McElduff, P., King, B. R., Smart, C. E., & Shafat, A. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13273 · Cited by 4
Antidiabetic Potential of Silver/Chitosan/Ascorbic Acid Nanocomposites
Mahmoud, E. A. A. E. Q., Mohamed, A. S., Fahmy, S. R., Soliman, A. M., & Gaafar, K. (2021) · Current Nanomedicine · doi:10.2174/2468187312666211220115859 · Cited by 4
Takahashi, H., Suganuma, Y., Ohno, T., & Nishimura, R. (2022) · Diabetology International · doi:10.1007/s13340-022-00577-y · Cited by 4
Chew, N., Muthiah, M. D., & Sanyal, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00003-6 · Cited by 5
Fayfman, M., Gewirtz, A. T., Delaroque, C., Blanco, G., Gibanica, S., Srinivasan, S., & Chassaing, B. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100256 · Cited by 4
“Metformin is one of the oldest and most widely used medications for the treatment of type 2 diabetes [1].”
BackgroundInfluentialPotential Role of GLP-1 Based Therapeutics in Coronary Artery Disease
Xiong, Q., Wang, J., Huang, K., Li, W., & Zhang, L. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2811315 · Cited by 4
“These drugs are commonly recommended as combination therapy in addition to metformin for patients who have not achieved their glycemic goals, particularly those who need to lose weight and reduce the risk of hypoglycemia [14].”
BackgroundMorillas, C., Escalada, J., Palomares, R., Bellido, D., Peralta, F. G., & Pérez, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0671-x · Cited by 4
Katsiki, N., & Παπάνας, Ν. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190328095249 · Cited by 4
Joo, S. H., Yang, S., Lee, S.-H., Park, S. J., Park, T., Rhee, S. Y., Cha, J. M., Rhie, S. J., Hwang, H. S., Kim, Y., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17101369 · Cited by 3
“KHIRB-MED-MDB-07-017), and written informed consent was exempted by the board.”
MethodKumar, M., Prabhakar, P., Hameed, S., Kumar, M., Shekhar, R., Kumar, B., & Dikshit, H. (2025) · International Journal of Applied and Basic Medical Research · doi:10.4103/ijabmr.ijabmr_580_24 · Cited by 3
“[12,13] Clerodendrum infortunatum Linn.”
Müller, F., Bouthillier, M. J., Alshaarawy, O., Azhary, H., & Holman, H. T. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/6656982 · Cited by 3
“Starting in 2018, these organizations recommended the use of SGLT2 inhibitors or GLP-1RAs for patients with established cardiovascular disease, heart failure, or chronic kidney disease [3, 4].”
Pawar, S. S., Rasal, P. B., Kulkarni, K. H., & Pawar, S. B. (2025) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v15i12.7452 · Cited by 4
Identification of a genetic risk factor for metformin-induced vitamin B12 deficiency
Baldwin, F. D., Bedair, K., Jorgensen, A., GREEN, L. A., Asiimwe, I. G., Palmer, C. N. A., Campbell, A., Hayward, C., Pan, Q., Shu, S., et al. (2026) · Diabetologia · doi:10.1007/s00125-025-06655-5 · Cited by 3
“Furthermore, most monitoring guidelines, including both the MHRA in the UK [9] and the ADA [33], suggest the need for ‘periodic’ vitamin B 12 monitoring but do not provide a monitoring frequency, which probably leads to lack of monitoring.”
Vurallı, D. (2026) · Pediatric Diabetes · doi:10.1155/pedi/5539725 · Cited by 3
“DPP-4 inhibitors, which prevent the breakdown of incretins, have shown potential in reducing reactive hypoglyaemia, though more research is needed to clarify their role in CF [142,143].”
Ashfaq, R., & Hussain, H. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2621091 · Cited by 3
“…(i) α-glucosidase inhibitors; (ii) sulfonylureas; (iii) dipeptidyl peptidase-4 (DPP-4) inhibitors; (iv) biguanides; (v) amylin analogues; (vi) meglitinides, (vii) GLP-1 receptor agonists, (viii) SGLT2 inhibitors, (ix) thiazolidinediones, (x) bile acid sequestrants, (xi) dopamine-2 agonists [2,9].”
The Case for Using Human Insulin
Davidson, M. B. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.06.033 · Cited by 3
Use of Insulin in the Inpatient Setting: Need for Continued Use
Kumar, S., & Molitch, M. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1183-9 · Cited by 3
Deerochanawong, C., Leelawattana, R., Kosachunhanun, N., & Tantiwong, P. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420935930 · Cited by 3
Yamaji, T., Harada, T., Hashimoto, Y., Nakano, Y., Kajikawa, M., Yoshimura, K., Aoki, G., Chayama, K., Goto, C., Mizobuchi, A., et al. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13705 · Cited by 3
Dahlquist, A., Jandali, D., Nauman, M. C., & Johnson, J. J. (2023) · International Journal Of Nutrition · doi:10.14302/issn.2379-7835.ijn-23-4737 · Cited by 3
Şahin, N. T., Ek, H., & Pehlivan, S. (2024) · Journal of Clinical Nursing · doi:10.1111/jocn.17482 · Cited by 3
Wang, A. C., Bitzas, S., Perez, D., Schwartz, J. A., Zaidi, S., Oster, J., & Bergese, S. D. (2025) · Life · doi:10.3390/life15030427 · Cited by 4
Detail glucose fluctuation and variability by continuous glucose monitoring (CGM)
Bando, H., Ebe, K., Muneta, T., Bando, M., & Yonei, Y. (2020) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2020.07.00196 · Cited by 3
Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
Petunina, N. A., Кузина, И. А., & Недосугова, Л. В. (2020) · Diabetes Mellitus · doi:10.14341/dm12487 · Cited by 4
Wang, J., Lee, I., Lee, W., Lin, S., Lee, W.-L., Liang, K., & Sheu, W. H. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001646 · Cited by 3
Overcoming psychological insulin resistance: A practical guide for healthcare professionals
Snoek, F. J., Fisher, L., Polonsky, W. H., Stuckey, H. L., Hessler, D., Tang, T. S., Hermanns, N., Mundet, X., Silva, M. L., Sturt, J. A., et al. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.03.001 · Cited by 3
Outcomes of second-line oral antidiabetic drugs in persons with young-onset type 2 diabetes
Yen, F., Wei, J. C., Liu, J., Hsu, C., & Hwu, C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108928 · Cited by 3
Medication Optimization for New Initiators of Empagliflozin for Diabetic Kidney Disease
Swanner, A. A., Hawley, C. E., Li, K., Triantafylidis, L. K., Li, J., & Paik, J. M. (2021) · Clinical Diabetes · doi:10.2337/cd21-0078 · Cited by 3
Does Metformin Treatment in Pediatric Population Cause Vitamin B12 Deficiency?
Taş, Ö., Kontbay, T., Doğan, Ö., Köse, E., Berberoğlu, M., Şıklar, Z., Tümer, L., & Eminoğlu, F. T. (2022) · Klinische Pädiatrie · doi:10.1055/a-1702-2614 · Cited by 4
Use of SGLT2 inhibitor/metformin fixed dose combination in Korea
Choi, H. E., Lee, J., Je, N. K., & Jeong, K. H. (2022) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2022.32.1.13 · Cited by 3
Hamaguchi, M., Yoshimura, Y., Nakajima, H., Tanaka, T., Hasegawa, G., Ishii, M., Okada, H., Mitsuhashi, K., Kitagawa, N., Okamura, T., et al. (2022) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.22-7 · Cited by 3
Alfaqih, M. A., Aljanabi, M., Ababneh, E., Khanfar, M., Alqudah, M., & Sater, M. S. (2023) · Medicina · doi:10.3390/medicina59050997 · Cited by 3
Zhu, X., Li, X., Yin, D., Yang, J., & Wei, R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01560-3 · Cited by 4
Liu, W., Gao, Y., Zhang, R., Gong, S., Wang, X., Wang, Y., Cai, X., Zhang, X., Xie, X., Han, X., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03820-5 · Cited by 3
“MDI is an effective means of achieving a glucose target and its main advantage over other insulin regimens is that can be used to lower glucose concentration to varying extents when accompanied by carbohydrate counting and self-management skills [14].”
Choxi, R., Roy, S., Stamatouli, A. M., Mayer, S., & Jovin, I. S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1756778 · Cited by 3
Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review
Elnour, A. A., Alhajri, N., Khidir, I. Y., Amoodi, A. A., Ahmed, S. A., & Sadeq, A. S. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200522214554 · Cited by 3
Matsuhisa, M., Odawara, M., Hirose, T., Koshida, R., Senda, M., Tanaka, Y., & Terauchi, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1810665 · Cited by 3
Pharmacotherapy of Type 2 Diabetes
Kaur, J., Famta, P., Khurana, N., Vyas, M., & Khatik, G. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_50 · Cited by 3
STUDIA: una aplicación para apoyar el conteo de carbohidratos simulando la dinámica de la glucosa
Builes-Montaño, C. E., Lema-Pérez, L., Monsalve-Arango, L. E., Naranjo-Cano, M. A., Duque, C. M. S., Garcia‐Tirado, J., & Álvarez, H. (2022) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.9.4.770 · Cited by 3
Improving Outcomes in Patients With Diabetes Mellitus
Aguilar, D. A. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.011971 · Cited by 3
Ji, L., Du, Y., Xu, M., Zhou, X., Mo, Z., Ma, J., Li, J., Li, Y., Lin, J., Wang, Y., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05460-0 · Cited by 3
Metformin, Chlorpropamide, and Glibenclamide: Interactions with Metal Ions and Cyclodextrins
González-Barbosa, J., Hipólito-Nájera, A. R., Gómez‐Balderas, R., Rodríguez‐Laguna, N., & Moya‐Hernández, R. (2023) · Mini-Reviews in Organic Chemistry · doi:10.2174/1570193x20666230117105443 · Cited by 2
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S90-S102
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4212810717
- Cited by
- 739
- References
- 81
- Citations by year
- 2026: 12 · 2025: 28 · 2024: 30 · 2023: 47 · 2022: 69 · 2021: 126 · 2020: 246 · 2019: 181
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Societies, Medical, United States, Practice Guidelines as Topic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.